Telomir Pharmaceuticals (NASDAQ:TELO) Stock Rating Upgraded by Wall Street Zen

Telomir Pharmaceuticals (NASDAQ:TELO) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other research firms have also weighed in on TELO. Rodman & Renshaw began coverage on shares of Telomir Pharmaceuticals in a report on Tuesday, January 13th. They issued a “buy” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Telomir Pharmaceuticals presently has a consensus rating of “Hold”.

Telomir Pharmaceuticals Stock Up 0.9%

NASDAQ:TELO opened at $1.14 on Friday. Telomir Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $5.40. The company has a fifty day moving average of $1.30 and a 200-day moving average of $1.40. The firm has a market capitalization of $39.19 million, a P/E ratio of -3.08 and a beta of -0.49.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in Telomir Pharmaceuticals in the 2nd quarter valued at about $95,000. Raymond James Financial Inc. increased its stake in shares of Telomir Pharmaceuticals by 4,101.9% in the third quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after purchasing an additional 73,547 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Telomir Pharmaceuticals in the second quarter worth about $81,000. Jane Street Group LLC bought a new stake in shares of Telomir Pharmaceuticals in the second quarter valued at approximately $62,000. Finally, XTX Topco Ltd purchased a new stake in shares of Telomir Pharmaceuticals during the 4th quarter valued at approximately $53,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.